A5056367409- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Hedgehog Signaling Pathway Studies
- Gastric Cancer Management and Outcomes
- Immune cells in cancer
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Colorectal and Anal Carcinomas
- Economic and Financial Impacts of Cancer
- PI3K/AKT/mTOR signaling in cancer
- COVID-19 and healthcare impacts
- Thermodynamic properties of mixtures
- Metastasis and carcinoma case studies
Ospedale Monaldi
2022-2024
University of Campania "Luigi Vanvitelli"
2017-2024
Azienda di Rilievo Nazionale ed Alta Specializzazione
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2019-2023
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2021
Roche (United States)
2020
Eli Lilly (United States)
2020
Boehringer Ingelheim (United States)
2020
Novartis (Switzerland)
2020
Incyte (United States)
2020
IntroductionControversy remains as to whether pathologic complete response (pCR) and major (MPR) represent surrogate end points for event-free survival (EFS) overall (OS) in neoadjuvant trials resectable NSCLC.MethodsA search of PubMed archives international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a arm with immune checkpoint blockade alone or combination chemotherapy were included. Those not providing information regarding pCR, MPR,...
<h2>ABSTRACT</h2><h3>Purpose</h3> Our previous works demonstrated the ability of metformin to revert resistance gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, optimal dose be used non-diabetic patients still remains defined. The phase I–II trial METformin Advanced Lung (METAL) was designed identify maximum tolerated and evaluate safety activity combined with...
Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR)) score, a clinical/biochemical prognostic 154 patients treated with second/further-line immunotherapy. This study’s aim was to validate score different population group. Methods: 193 were...
Introduction Artificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed model predict efficacy of immunotherapy (IO) patients with advanced non-small cell lung cancer (NSCLC) using eXplainable AI (XAI) Machine Learning (ML) methods. Methods We prospectively collected real-world data from an NSCLC condition receiving immune-checkpoint inhibitors (ICIs) either single agent or...
Pioglitazone, a synthetic peroxisome proliferator activated receptor (PPAR-γ) ligand, is known as an antidiabetic drug included in the thiazolidinediones (TZDs) class. It regulates lipid and glucose cell metabolism recently role inhibition of numerous cancer processes has been described.
BackgroundAntibody-dependent cell-mediated cytotoxicity (ADCC) may mediate antitumour activity of IgG1-isotype monoclonal antibody (mAb), suggesting as potential treatment combination IgG1-mAbs, anti-epidermal growth factor receptor cetuximab and anti-programmed death-ligand-1 avelumab.MethodsWe evaluated ADCC induction in lung cancer cells by lactate dehydrogenase (LDH) release assay. Antitumour safety plus avelumab were explored a single-arm proof-of-concept study pre-treated non-small...
In the era of precision medicine, research studies are aiming to design patient-tailored treatment strategies. this work, we present a clinical case patient with non-small cell lung cancer (NSCLC) accompanied by translational study intent assess correspondence drug sensitivity in ex vivo spheroidal tumour cultures and peripheral blood biomarkers outcome.Primary tissue, patient-derived spheroids, mononuclear cells circulating DNA were analysed immunological profiling, all these data...
Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) <50%. Although single-agent pembrolizumab has also demonstrated some activity in this setting, no reliable biomarkers yet exist selecting likely to respond immunotherapy. The main purpose study was identify potential new associated progression-free-survival (PFS) within a multiomics analysis. Methods PEOPLE (NTC03447678)...